Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.

<h4>Background</h4>To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria. This systematic review and individua...

Full description

Saved in:
Bibliographic Details
Main Authors: Benedikt Ley, Ari Winasti Satyagraha, Hisni Rahmat, Michael E von Fricken, Nicholas M Douglas, Daniel A Pfeffer, Fe Espino, Lorenz von Seidlein, Gisela Henriques, Nwe Nwe Oo, Didier Menard, Sunil Parikh, Germana Bancone, Amalia Karahalios, Ric N Price
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-12-01
Series:PLoS Medicine
Online Access:https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002992&type=printable
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850128181663629312
author Benedikt Ley
Ari Winasti Satyagraha
Hisni Rahmat
Michael E von Fricken
Nicholas M Douglas
Daniel A Pfeffer
Fe Espino
Lorenz von Seidlein
Gisela Henriques
Nwe Nwe Oo
Didier Menard
Sunil Parikh
Germana Bancone
Amalia Karahalios
Ric N Price
author_facet Benedikt Ley
Ari Winasti Satyagraha
Hisni Rahmat
Michael E von Fricken
Nicholas M Douglas
Daniel A Pfeffer
Fe Espino
Lorenz von Seidlein
Gisela Henriques
Nwe Nwe Oo
Didier Menard
Sunil Parikh
Germana Bancone
Amalia Karahalios
Ric N Price
author_sort Benedikt Ley
collection DOAJ
description <h4>Background</h4>To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria. This systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from Access Bio/CareStart (Somerset, NJ) (CareStart Screening test for G6PD deficiency) for the diagnosis of G6PDd compared to the gold standard spectrophotometry (International Prospective Register of Systematic Reviews [PROSPERO]: CRD42019110994).<h4>Methods and findings</h4>Articles published on PubMed between 1 January 2011 and 27 September 2019 were screened. Articles reporting performance of the standard CSG from venous or capillary blood samples collected prospectively and considering spectrophotometry as gold standard (using kits from Trinity Biotech PLC, Wicklow, Ireland) were included. Authors of articles fulfilling the inclusion criteria were contacted to contribute anonymized individual data. Minimal data requested were sex of the participant, CSG result, spectrophotometry result in U/gHb, and haemoglobin (Hb) reading. The adjusted male median (AMM) was calculated per site and defined as 100% G6PD activity. G6PDd was defined as an enzyme activity of less than 30%. Pooled estimates for sensitivity and specificity, unconditional negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) were calculated comparing CSG results to spectrophotometry using a random-effects bivariate model. Of 11 eligible published articles, individual data were available from 8 studies, 6 from Southeast Asia, 1 from Africa, and 1 from the Americas. A total of 5,815 individual participant data (IPD) were available, of which 5,777 results (99.3%) were considered for analysis, including data from 3,095 (53.6%) females. Overall, the CSG had a pooled sensitivity of 0.96 (95% CI 0.90-0.99) and a specificity of 0.95 (95% CI 0.92-0.96). When the prevalence of G6PDd was varied from 5% to 30%, the unconditional NPV was 0.99 (95% CI 0.94-1.00), with an LR+ and an LR- of 18.23 (95% CI 13.04-25.48) and 0.05 (95% CI 0.02-0.12), respectively. Performance was significantly better in males compared to females (p = 0.027) but did not differ significantly between samples collected from capillary or venous blood (p = 0.547). Limitations of the study include the lack of wide geographical representation of the included data and that the CSG results were generated under research conditions, and therefore may not reflect performance in routine settings.<h4>Conclusions</h4>The CSG performed well at the 30% threshold. Its high NPV suggests that the test is suitable to guide PQ treatment, and the high LR+ and low LR- render the test suitable to confirm and exclude G6PDd. Further operational studies are needed to confirm the utility of the test in remote endemic settings.
format Article
id doaj-art-b1a16a0ff1b54596b8a8499838df42ce
institution OA Journals
issn 1549-1277
1549-1676
language English
publishDate 2019-12-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS Medicine
spelling doaj-art-b1a16a0ff1b54596b8a8499838df42ce2025-08-20T02:33:25ZengPublic Library of Science (PLoS)PLoS Medicine1549-12771549-16762019-12-011612e100299210.1371/journal.pmed.1002992Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.Benedikt LeyAri Winasti SatyagrahaHisni RahmatMichael E von FrickenNicholas M DouglasDaniel A PfefferFe EspinoLorenz von SeidleinGisela HenriquesNwe Nwe OoDidier MenardSunil ParikhGermana BanconeAmalia KarahaliosRic N Price<h4>Background</h4>To reduce the risk of drug-induced haemolysis, all patients should be tested for glucose-6-phosphate dehydrogenase (G6PD) deficiency (G6PDd) prior to prescribing primaquine (PQ)-based radical cure for the treatment of vivax malaria. This systematic review and individual patient meta-analysis assessed the utility of a qualitative lateral flow assay from Access Bio/CareStart (Somerset, NJ) (CareStart Screening test for G6PD deficiency) for the diagnosis of G6PDd compared to the gold standard spectrophotometry (International Prospective Register of Systematic Reviews [PROSPERO]: CRD42019110994).<h4>Methods and findings</h4>Articles published on PubMed between 1 January 2011 and 27 September 2019 were screened. Articles reporting performance of the standard CSG from venous or capillary blood samples collected prospectively and considering spectrophotometry as gold standard (using kits from Trinity Biotech PLC, Wicklow, Ireland) were included. Authors of articles fulfilling the inclusion criteria were contacted to contribute anonymized individual data. Minimal data requested were sex of the participant, CSG result, spectrophotometry result in U/gHb, and haemoglobin (Hb) reading. The adjusted male median (AMM) was calculated per site and defined as 100% G6PD activity. G6PDd was defined as an enzyme activity of less than 30%. Pooled estimates for sensitivity and specificity, unconditional negative predictive value (NPV), positive likelihood ratio (LR+), and negative likelihood ratio (LR-) were calculated comparing CSG results to spectrophotometry using a random-effects bivariate model. Of 11 eligible published articles, individual data were available from 8 studies, 6 from Southeast Asia, 1 from Africa, and 1 from the Americas. A total of 5,815 individual participant data (IPD) were available, of which 5,777 results (99.3%) were considered for analysis, including data from 3,095 (53.6%) females. Overall, the CSG had a pooled sensitivity of 0.96 (95% CI 0.90-0.99) and a specificity of 0.95 (95% CI 0.92-0.96). When the prevalence of G6PDd was varied from 5% to 30%, the unconditional NPV was 0.99 (95% CI 0.94-1.00), with an LR+ and an LR- of 18.23 (95% CI 13.04-25.48) and 0.05 (95% CI 0.02-0.12), respectively. Performance was significantly better in males compared to females (p = 0.027) but did not differ significantly between samples collected from capillary or venous blood (p = 0.547). Limitations of the study include the lack of wide geographical representation of the included data and that the CSG results were generated under research conditions, and therefore may not reflect performance in routine settings.<h4>Conclusions</h4>The CSG performed well at the 30% threshold. Its high NPV suggests that the test is suitable to guide PQ treatment, and the high LR+ and low LR- render the test suitable to confirm and exclude G6PDd. Further operational studies are needed to confirm the utility of the test in remote endemic settings.https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002992&type=printable
spellingShingle Benedikt Ley
Ari Winasti Satyagraha
Hisni Rahmat
Michael E von Fricken
Nicholas M Douglas
Daniel A Pfeffer
Fe Espino
Lorenz von Seidlein
Gisela Henriques
Nwe Nwe Oo
Didier Menard
Sunil Parikh
Germana Bancone
Amalia Karahalios
Ric N Price
Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
PLoS Medicine
title Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
title_full Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
title_fullStr Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
title_full_unstemmed Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
title_short Performance of the Access Bio/CareStart rapid diagnostic test for the detection of glucose-6-phosphate dehydrogenase deficiency: A systematic review and meta-analysis.
title_sort performance of the access bio carestart rapid diagnostic test for the detection of glucose 6 phosphate dehydrogenase deficiency a systematic review and meta analysis
url https://journals.plos.org/plosmedicine/article/file?id=10.1371/journal.pmed.1002992&type=printable
work_keys_str_mv AT benediktley performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT ariwinastisatyagraha performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT hisnirahmat performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT michaelevonfricken performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT nicholasmdouglas performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT danielapfeffer performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT feespino performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT lorenzvonseidlein performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT giselahenriques performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT nwenweoo performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT didiermenard performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT sunilparikh performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT germanabancone performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT amaliakarahalios performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis
AT ricnprice performanceoftheaccessbiocarestartrapiddiagnostictestforthedetectionofglucose6phosphatedehydrogenasedeficiencyasystematicreviewandmetaanalysis